Neuren Pharmaceuticals Competitors and Similar CompaniesClear all
Neuren Pharmaceuticals's competitors and similar companies include Delix Therapeutics, Autifony Therapeutics, Adverum Biotechnologies and SwanBio Therapeutics.
 Neuren Pharmaceuticals Neuren Pharmaceuticals is a company that develops therapies for debilitating neurodevelopmental disorders. |  Delix Therapeutics Delix Therapeutics is a company developing small molecule drug compounds against mental disorders. |  Autifony Therapeutics Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system. |  Adverum Biotechnologies Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases. |  SwanBio Therapeutics SwanBio Therapeutics is a gene therapy company developing medicines for the treatment of neurological diseases. | |
Founding Date | Founding Date 1993 | Founding Date 2019 | Founding Date 2011 | Founding Date 2006 | Founding Date 2018 |
Type | Type Public | Type Private | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Camberwell, AU HQ Auckland, NZ | Locations HQ | Locations Stevenage, GB HQ Padova, IT | Locations Redwood City, US HQ Philadelphia, US | Locations Philadelphia, US HQ Cambridge, US |
Employees | Employees N/A | Employees 313% decrease | Employees 3017% decrease | Employees 11419% increase | Employees 625% decrease |
Valuation ($) | Valuation ($) 1.3 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 161.4 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $64.6m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) £22.8m (FY, 2018) | Revenue (est.) $1m (FY, 2024) | Revenue (est.) N/A |
Net income | Net income $30.4m (FY, 2025) | Net income N/A | Net income £16.2m (FY, 2018) | Net income ($130.9m) (FY, 2024) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 70m (over 4 years ago) | Latest funding round $ 12.3m (almost 11 years ago) | Latest funding round N/A | Latest funding round $ 52m (about 6 years ago) |
Total funding raised | Total funding raised $ 21.5m | Total funding raised $ 78m | Total funding raised $ 24.2m | Total funding raised $ 70.7m | Total funding raised $ 52m |
For sources of this data, please see the company profile
View Company Profiles
Delix Therapeutics
HQ
Employees
31↓ 3% decrease
Delix Therapeutics is a company developing small molecule drug compounds against mental disorders.
View companyAutifony Therapeutics
HQ
Stevenage, GB
Employees
30↓ 17% decrease
Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system.
View companyAdverum Biotechnologies
HQ
Redwood City, US
Employees
114↑ 19% increase
Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases.
View companySwanBio Therapeutics
HQ
Philadelphia, US
Employees
6↓ 25% decrease
SwanBio Therapeutics is a gene therapy company developing medicines for the treatment of neurological diseases.
View company